You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 2, February 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (135)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Skin Changes Secondary to Hydroxyurea Therapy

B. J. Kennedy, MD; L. Robert Smith, MD; Robert W. Goltz, MD

Arch Dermatol. 1975;111(2):183-187.


Abstract

Hydroxyurea is an effective agent in the treatment of chronic myelogenous leukemia. The toxic reactions have included myelosuppression and megaloblastosis. During long-term maintenance therapy, dermatologic alterations occurred in seven of 20 patients and consisted of partial alopecia, increased pigmentation, scaling, atrophy of the skin and subcutaneous tissues, nail changes, and erythema of the face and hands. The histologic changes were similar to those seen in lichen planus. These observations were a factor leading to the use of hydroxyurea in the treatment of psoriasis.



Author Affiliations

From the Section of Medical Oncology, departments of medicine and dermatology, University of Minnesota School of Medicine, Minneapolis.


Footnotes

Accepted for publication Aug 12, 1974.

Reprint requests to Section of Medical Oncology, Department of Medicine, Box 286, University Hospitals, Minneapolis, MN 55455 (Dr. Kennedy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment
Tefferi and Barbui
Mayo Clin Proc. 2005;80:1220-1232.
ABSTRACT  

Cutaneous Adverse Reactions to Hydroxyurea in Patients With Sickle Cell Disease
Chaine et al.
Arch Dermatol 2001;137:467-470.
ABSTRACT | FULL TEXT  

Localised chronic eyelid disease resulting from long term hydroxyurea therapy
PURI et al.
Br J Ophthalmol 2001;85:371b-371.
FULL TEXT  

Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera
Tefferi et al.
Blood 2000;96:1582-1584.
ABSTRACT | FULL TEXT  

A Case of Bilateral Heel Ulcers Associated with Hydroxyurea Therapy for Chronic Myelogenous Leukemia
Tarumoto et al.
Jpn J Clin Oncol 2000;30:159-162.
ABSTRACT | FULL TEXT  

Successful Healing of Hydroxyurea-Related Leg Ulcers With Topical Granulocyte-Macrophage Colony-Stimulating Factor
Stagno et al.
Blood 1999;94:1479-1480.
FULL TEXT  

Hydroxyurea in Sickle Cell Disease
Schechter et al.
NEJM 1996;334:333-334.
FULL TEXT  

Chemotherapy-Induced Acral Erythema in Patients Receiving Bone Marrow Transplantation
Crider et al.
Arch Dermatol 1986;122:1023-1027.
ABSTRACT  

Chemotherapy-Induced Transverse White Lines in the Fingernails
James and Odom
Arch Dermatol 1983;119:334-335.
ABSTRACT  

Fever Caused by Hydroxyurea
Bauman et al.
Arch Intern Med 1981;141:260-261.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.